Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Large Decrease in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 97,300 shares, a decline of 99.4% from the January 15th total of 15,930,000 shares. Based on an average trading volume of 1,530,000 shares, the short-interest ratio is currently 0.1 days. Currently, 1.7% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Monday. They issued a “sell” rating for the company.

Institutional Trading of Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. Commonwealth Equity Services LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 120,292 shares of the company’s stock, valued at approximately $40,000. Commonwealth Equity Services LLC owned 6.43% of Tonix Pharmaceuticals as of its most recent SEC filing. 82.26% of the stock is owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Price Performance

TNXP stock traded down $0.03 during trading on Wednesday, reaching $11.92. 454,178 shares of the company were exchanged, compared to its average volume of 1,545,993. The company has a 50-day moving average of $29.36 and a two-hundred day moving average of $25.32. The company has a market capitalization of $22.28 million, a price-to-earnings ratio of 0.00 and a beta of 2.07. Tonix Pharmaceuticals has a twelve month low of $10.82 and a twelve month high of $1,248.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($23.00) earnings per share for the quarter, beating the consensus estimate of ($203.00) by $180.00. The company had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, equities analysts predict that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.